Apoptosis Immunology/Inflammation PI3K/Akt/mTOR Epigenetics Stem Cell/Wnt Protein Tyrosine Kinase/RTK JAK/STAT Signaling Neuronal Signaling Membrane Transporter/Ion Channel NF-κB Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor Cell Cycle/DNA Damage
Apoptosis Pyroptosis AMPK Bcl-2 Family JAK STAT Calcium Channel Interleukin Related TNF Receptor SOD Reactive Oxygen Species (ROS) PPAR
Calenduloside E

Art. -Nr.: HY-N6850

Calenduloside E

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated JAK1-STAT3 pathways to reduce cellular inflammatory responses.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.07%
CAS. Nr.: 26020-14-4
Formel: C₃₆H₅₆O₉
Molecular Weight:632.82

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Calenduloside E Chemical Structure

CAS. Nr.: 26020-14-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle AMPK Isoform-spezifische Produkte anzeigen :

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Alle JAK Isoform-spezifische Produkte anzeigen :

Alle STAT Isoform-spezifische Produkte anzeigen :

Alle Calcium Channel Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Alle TNF Receptor Isoform-spezifische Produkte anzeigen :

Alle PPAR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	18 μM Compound: OAG	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00502G
MCF7	IC₅₀	11.33 μM Compound: OAG	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00502G
MOLT-4	IC₅₀	13.34 μM Compound: OAG	Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00502G
NCI-H460	IC₅₀	6 μM Compound: 18	Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by cell-titer 96 aqueous non-radioactive cell proliferation assay Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by cell-titer 96 aqueous non-radioactive cell proliferation assay	[PMID: 26287548]
SK-BR-3	IC₅₀	11.88 μM Compound: OAG	Cytotoxicity against human SKBR3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SKBR3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	10.1039/C5MD00502G

In Vitro

Calenduloside E (1.25 μg/mL; 24 h) inhibits glycolysis-mediated M1 macrophage polarization^[2].
Calenduloside E (1 μM; 2 h) alleviates LPS (HY-D1056)/D-galn-induced AML12 and LX2 cell damage and AMPK-SIRT3 signaling pathway protein expression^[3].
Calenduloside E (0-16 μM; 24 h) inhibits inflammasome activation and pyroptosis in AML-12 cells stimulated by lipid mixture^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

ox-LDL-induced M1 macrophages
Concentration:

1.25 μg/mL
Incubation Time:

24 h
Result:

Reduced the levels of IL-1 β, IL-6, PFKFB3, GLUT1 and LDHA.

Western Blot Analysis^[3]

Cell Line:

LPS/ d-galn-induced AML12 and LX2 cells
Concentration:

1 μM
Incubation Time:

2 h
Result:

Reduced ROS and JC-1 levels, as well as cell apoptosis.

Immunofluorescence^[5]

Cell Line:

AML-12 cells stimulated with lipid mixture
Concentration:

2, 4, 8 and 16 μM
Incubation Time:

24 h
Result:

Inhibited the increased expression of NLRP3, Caspase-1 p20, and IL-1β.

In Vivo

Calenduloside E (11 mg/kg; i.g.; once daily for 16 weeks) reduces atherosclerotic plaque size, enhanced plaque stability, and reduced inflammatory responses in ApoE-/- mice^[2].
Calenduloside E (15 and 30 mg/kg; i.g.; once daily for 7 days) inhibits hepatocyte apoptosis and reduced oxidative stress and immune inflammation in mice with acute liver injury induced by LPS (HY-D1056) and D-GalN^[3].
Calenduloside E (7.5-30 mg/kg; i.g.; once daily for 3 days) restores sarcomere contraction and calcium transients in adult rat ventricular myocytes (ARVMs)^[4].
Calenduloside E (5 and 10 mg/kg; i.g.; once daily for 4 weeks) improves liver injury, lipid accumulation, and profibrotic phenotypes in nonalcoholic fatty liver disease model mice and inhibits inflammasome activation and pyroptosis in the liver of mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

HFD-fed ApoE-/- mice^[2]
Dosage:

11 mg/kg
Administration:

i.g.；Once a day for 16 weeks
Result:

Reduced the levels of IL-1β, IL-6, TNF-α, and monocyte chemoattractant protein-1 (MCP-1) in the serum of ApoE-/- mice.

Animal Model:

LPS (HY-D1056)/dGalN-induced acute liver injury in mice^[3]
Dosage:

15 and 30 mg/kg
Administration:

i.g.; 1 time per day for 7 consecutive days
Result:

Improved hepatocyte infiltration and reduced hepatocyte necrosis and shrinkage.
Reduced hepatocyte ROS levels and serum MDA levels, and increased GSH-Px and SOD levels.

Animal Model:

Rat Model of MI/R Injury^[4]
Dosage:

7.5, 15 and 30 mg/kg
Administration:

i.g.; 1 time per day for 3 consecutive days
Result:

Myocardial infarction area/risk area decreased to 53%, 38% and 43% respectively.
Restored the expression of calcium-regulating proteins, including calcium transporters (SERCA, a1C, RyR2, and NCX) to normal levels.

Animal Model:

Establishment of NAFLD model in apoE-/- mice by western diet^[5]
Dosage:

5 and 10 mg/kg
Administration:

i.g.; 1 time per day for 4 weeks
Result:

Reduced the expression of TNF-α, MCP-1, CCL2, Ly6c and cd68 in the liver.
Reversed the upregulation of lipogenic genes FASN, Srebpf, ACC and PPARγ and lipid uptake gene cd36.
Reduced the expression of NLRP3, pNLRC4, NLRC4, cleaved GSDMD, cleaved Caspase1 and IL-1β.

Chemical Information

CAS. Nr. 26020-14-4
Appearance Solid
Molecular Weight 632.82
Formel C₃₆H₅₆O₉
Color White to off-white
SMILES

C[C@]12[C@]3(C([C@@]4([H])[C@](C(O)=O)(CCC(C)(C)C4)CC3)=CC[C@]1([H])[C@@]5([C@@](C(C)([C@@H](O[C@]6([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O)CC5)C)([H])CC2)C)C
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

J Mol Histol

Calenduloside E alleviates cerebral ischemia/reperfusion injury by preserving mitochondrial function. [Abstract]

2022 Aug;53(4):713-727. PMID: 35819738

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (158.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5802 mL

7.9011 mL

15.8023 mL

5 mM

0.3160 mL

1.5802 mL

3.1605 mL

10 mM

0.1580 mL

0.7901 mL

1.5802 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Tian Y, et al. The clickable activity-based probe of anti-apoptotic calenduloside E. Pharm Biol. 2019 Dec;57(1):133-139. [Content Brief]

[2]. Lanfang Li, et al. "Calenduloside e modulates macrophage polarization via KLF2-regulated glycolysis, contributing to attenuates atherosclerosis." International Immunopharmacology 117 (2023): 109730. [Content Brief]

[3]. Pengli Guo, et al. "Isolation of Calenduloside E from achyranthes bidentata blume and its effects on LPS/D-GalN-induced acute liver injury in mice by regulating the AMPK-SIRT3 signaling pathway." Phytomedicine 125 (2024): 155353. [Content Brief]

[4]. Ruiying Wang, et al. "Calenduloside E suppresses calcium overload by promoting the interaction between L-type calcium channels and Bcl2-associated athanogene 3 to alleviate myocardial ischemia/reperfusion injury." Journal of Advanced Research 34 (2021): 173-186. [Content Brief]

[5]. Yifei Le, et al. "Calenduloside E ameliorates non-alcoholic fatty liver disease via modulating a pyroptosis-dependent pathway." Journal of Ethnopharmacology 319 (2024): 117239. [Content Brief]

[6]. Min Wang, et al. "Calenduloside E ameliorates myocardial ischemia‐reperfusion injury through regulation of AMPK and mitochondrial OPA1." Oxidative Medicine and Cellular Longevity 2020.1 (2020): 2415269. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.5802 mL	7.9011 mL	15.8023 mL	39.5057 mL
	5 mM	0.3160 mL	1.5802 mL	3.1605 mL	7.9011 mL
	10 mM	0.1580 mL	0.7901 mL	1.5802 mL	3.9506 mL
	15 mM	0.1053 mL	0.5267 mL	1.0535 mL	2.6337 mL
	20 mM	0.0790 mL	0.3951 mL	0.7901 mL	1.9753 mL
	25 mM	0.0632 mL	0.3160 mL	0.6321 mL	1.5802 mL
	30 mM	0.0527 mL	0.2634 mL	0.5267 mL	1.3169 mL
	40 mM	0.0395 mL	0.1975 mL	0.3951 mL	0.9876 mL
	50 mM	0.0316 mL	0.1580 mL	0.3160 mL	0.7901 mL
	60 mM	0.0263 mL	0.1317 mL	0.2634 mL	0.6584 mL
	80 mM	0.0198 mL	0.0988 mL	0.1975 mL	0.4938 mL
	100 mM	0.0158 mL	0.0790 mL	0.1580 mL	0.3951 mL

Keywords

Calenduloside E

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Calenduloside E

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Terpenoids Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Ion Channel Compound Library

Anti-Hematopathy Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Fatty Acids Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library